In this case, clinical data sets were available for inhibitors of closely connected targets (EGFR, BRAF, and MEK) in the same indication (BRAFV600E-CRC), and this data was necessary to statistically constrain the clinical simulations and make accurate predictions. This evidence concerns the gene EGFR and colorectal carcinoma.